About: Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
Creator	Edwards, Michael Bartlett, Nathan Johnston, Sebastian Belvisi, Maria Birrell, Mark »more»
source	Elsevier; Medline; PMC
abstract	Abstract Asthma and chronic obstructive pulmonary disease are inflammatory lung disorders responsible for significant morbidity and mortality worldwide. While the importance of allergic responses in asthma is well known, respiratory viral and bacterial infections and pollutants especially cigarette smoke are important factors in the pathogenesis of both diseases. Corticosteroid treatment remains the first preference of treatment in either disease, however these therapies are not always completely effective, and are associated with side effects and steroid resistance. Due to such limitations, development of new treatments represents a major goal for both the pharmaceutical industry and academic researchers. There are now excellent reasons to promote NF-κB signalling intermediates and Rel family proteins as potential therapeutic targets for both asthma and chronic obstructive pulmonary disease. This notion is supported by the fact that much of the underlying inflammation of both diseases independent of stimuli, is mediated at least in part, by NF-κB mediated signalling events in several cell types. Also, a range of inhibitors of NF-κB signalling intermediates are now available, including DNA oligonucleotides and DNA-peptide molecules that act as NF-κB decoy sequences, small molecule inhibitors such as IKK-β inhibitors, and proteasome inhibitors affecting NF-κB signalling, that have either shown promise in animal models or have begun clinical trials in other disorders. This review will focus on the role of NF-κB in both diseases, will discuss its suitability as a target, and will highlight recent key studies that support the potential of NF-κB as a therapeutic target in these two important inflammatory lung diseases.
has issue date	2009-01-31(xsd:dateTime)
bibo:doi	10.1016/j.pharmthera.2008.09.003
bibo:pmid	18950657
has license	els-covid
sha1sum (hex)	b8857e293f7343fb20ab2ab031e01eab7ce7f074
schema:url	https://doi.org/10.1016/j.pharmthera.2008.09.003
resource representing a document's title	Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
has PubMed Central identifier	PMC7172981
has PubMed identifier	18950657
schema:publication	Pharmacology & Therapeutics
resource representing a document's body	covid:b8857e293f7343fb20ab2ab031e01eab7ce7f074#body_text
is schema:about of	named entity 'asthma' named entity 'cytokines' named entity 'TCR' named entity 'cell clones' named entity 'AHR' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software